{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:45:23Z","timestamp":1794408323903,"version":"4.9.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s12185-019-02613-1","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T03:46:10Z","timestamp":1550115970000},"page":"426-439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system"],"prefix":"10.1007","volume":"109","author":[{"name":"the New TARGET investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kizaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koiti","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"2613_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12185-008-0186-0","volume":"88","author":"M Kizaki","year":"2008","unstructured":"Kizaki M, Okamoto S, Tauchi T, Tanaka H, Tanimoto M, Inokuchi K, et al. Current and future perspectives on the TARGET system: the registration system for Glivec\u00ae established by the JSH. Int J Hematol. 2008;88:409\u201317.","journal-title":"Int J Hematol"},{"key":"2613_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.leukres.2010.10.027","volume":"35","author":"T Tauchi","year":"2011","unstructured":"Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res. 2011;35:585\u201390.","journal-title":"Leuk Res"},{"key":"2613_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"2613_CR4","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"2613_CR5","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"issue":"5","key":"2613_CR6","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354.","journal-title":"Leukemia"},{"key":"2613_CR7","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"2613_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12185-017-2353-7","volume":"107","author":"H Nakamae","year":"2018","unstructured":"Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2018;107:327\u201336.","journal-title":"Int J Hematol"},{"key":"2613_CR9","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12185-017-2208-2","volume":"105","author":"H Nakamae","year":"2017","unstructured":"Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol. 2017;105:792\u2013804.","journal-title":"Int J Hematol"},{"key":"2613_CR10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2015","unstructured":"Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood. 2015;125:901\u20136.","journal-title":"Blood"},{"key":"2613_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","volume":"2","author":"J Douxfils","year":"2016","unstructured":"Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogn\u00e9 JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2:625\u2013632","journal-title":"JAMA Oncol"},{"key":"2613_CR12","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s00277-018-3412-8","volume":"97","author":"I Fujioka","year":"2018","unstructured":"Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, et al. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol. 2018;97:2081\u20138.","journal-title":"Ann Hematol"},{"key":"2613_CR13","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarijan H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"2613_CR14","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26:2096\u2013102.","journal-title":"Leukemia"},{"key":"2613_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqu\u00e9 C, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494\u2013500.","journal-title":"Blood"},{"key":"2613_CR16","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","volume":"121","author":"P Jain","year":"2013","unstructured":"Jain P, Kantarjian H, Nazha A, O\u2019Brien S, Jabbour E, Romo CG, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013;121:4867\u201374.","journal-title":"Blood"},{"key":"2613_CR17","unstructured":"NCCN. Chronic myeloid leukemia. NCCN clinical practice guidelines in oncology; Version 1:16. 2019"},{"key":"2613_CR18","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv41\u201351.","journal-title":"Ann Oncol"},{"key":"2613_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17\u201323.","journal-title":"Blood"},{"key":"2613_CR20","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","volume":"57","author":"C Chai-Adisaksopha","year":"2016","unstructured":"Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2016;57:1300\u201310.","journal-title":"Leuk Lymphoma"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02613-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02613-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02613-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T19:39:39Z","timestamp":1581622779000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02613-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["2613"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02613-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,14]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M. Kizaki reports personal fees from Bristol-Myers Squibb, Celgene, Nippon Shinyaku, Takeda Pharmaceutical, and Ono Pharmaceutical, and grants from Kyowa Hakko Kirin, Chugai Pharmaceutical, and Pfizer, outside the submitted work; N. Takahashi reports grants and personal fees from Novartis Pharmaceuticals, Pfizer, and Otsuka Pharmaceutical, personal fees from Bristol-Myers Squibb, and grants from Kyowa Hakko Kirin, Astellas Pharma, Chugai Pharmaceutical, Asahi Kasei Pharma, Ono Pharmaceutical, and Eisai Pharmaceuticals, outside the submitted work; S. Okamoto reports grants and personal fees from Otsuka Pharmaceutical, Novartis Pharmaceuticals, Bristol-Meyer Squib, Astellas Pharma, Kyowa Hakko Kirin, and Chugai Pharmaceutical, and personal fees from Pfizer, outside the submitted work; T. Ono reports grants from Celgene, Kyowa Hakko Kirin, Chugai Pharmaceutical, and Merck Sharp & Dohme, and personal fees from Novartis Pharmaceuticals, Bristol-Myers Squibb, Pfizer, and Otsuka Pharmaceutical, outside the submitted work; N. Usui reports personal fees from AbbVie Inc., Astellas Pharma, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical, CIMIC, Huya Bioscience International, Kyowa Hakko Kirin, Nippon Shinyaku Pharmaceutical, Daiichi Sankyo, Otsuka Pharmaceutical, Pfizer, SymBio Pharmaceuticals, Sysmex, Takeda Pharmaceutical, Takara Bio Inc., Sumitomo Dainippon Pharma, Zenyaku Kogyo, Alexion Pharmaceuticals, Taisho Toyama Pharmaceutical, Mochida Pharmaceutical, Ono Pharmaceutical, Taiho Pharmaceutical, and Meiji Seika Pharma, outside the submitted work; K. Inokuchi reports grants and personal fees from Bristol-Myers Squibb, personal fees from Novartis Pharmaceuticals, Celgene, and Pfizer, outside the submitted work; C. Nakaseko reports grants and personal fees from Pfizer, grants from Kyowa Hakko Kirin, Daiichi Sankyo, Astellas Pharma, Ono Pharmaceutical, Takeda Pharmaceutical, and Chugai Pharmaceutical, personal fees from Novartis Pharmaceuticals, and Celgene, outside the submitted work; M. Kurokawa reports grants from Novartis Pharmaceuticals, Bristol-Meyer Squib, Astellas Pharma, Kyowa Hakko Kirin, Pfizer, Takeda Pharmaceutical, Ono Pharmaceutical, and Nippon Shinyaku Pharmaceutical, and personal fees from Celgene, and Shionogi, outside the submitted work; T. Kawaguchi reports grants and personal fees from MSD, and personal fees from Pfizer, Alexion Pharma, and Novartis Pharmaceuticals, outside the submitted work; R. Suzuki reports personal fees from Bristol-Meyer Squib, Novartis Pharmaceuticals, Kyowa-Hakko Kirin, Chugai Pharmaceutical, Shionogi, Takeda Pharmaceutical, Meiji Seika Pharma, MSD, Otsuka Pharmaceutical, Sawai, Celgene, Sumitomo Dainippon Pharma, Eisai Pharmaceuticals, Alexion Pharma, Sanofi, Gilead Sciences, Abbvie Inc., Mundi Pharma, Jazz Pharma, Ono Pharmaceutical, and Janssen Pharmaceuticals, outside the submitted work; K. Yamamoto reports grants and personal fees from Astra-Zeneca, Celgene, Chugai Pharmaceutical, Eisai Pharmaceuticals, MSD, Novartis Pharmaceuticals, Ono Pharmaceutical, Takeda Pharmaceutical, and Zenyaku, and grants from AbbVie Inc., ARIAD, Bayer, Gilead Sciences, Solasia Pharma, and SymBio, and personal fees from Bristol-Myers Squibb, Kyowa Hakko Kirin, Meiji Seika Pharma, Mochida, Mundipharma, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, and Boehringer Ingelheim, outside the submitted work; I. Matsumura reports grants and personal fees from Bristol-Myers Squibb, Novartis Pharmaceuticals, during the conduct of the study, grants and personal fees from Nippon Shinyaku Pharmaceutical, Celgene, Pfizer, Otsuka Pharmaceutical, Kyowa Hakko Kirin, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Shionogi, and Teijin Pharma, personal fees from Janssen Pharmaceutical, Boehringer Ingelheim, Sanofi, grants from Chugai Pharmaceutical, Eisai Pharmaceuticals, MSD, Asahi Kasei Pharma, Astellas Pharma, Takeda Pharmaceutical, Japan Blood Products Organization, Nihon Pharmaceutical, and Daiichi Sankyo, outside the submitted work; the other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}